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Adding hyperthermia to standard radiotherapy (RT + HT) improves treatment outcome for
patients with locally advanced cervical cancer (LACC). We investigated the effect of hyper-
thermia dose on treatment outcome for patients with LACC treated with RT + HT.
We collected treatment and outcome data of 420 patients with LACC treated with hyper-
thermia at our institute from 1990 to 2005. Univariate and multivariate analyses were per-
formed on response rate, local control, disease-specific survival and toxicity for these
patients to search for a thermal dose response relationship.
Besides commonly identified prognostic factors in LACC like tumour stage, performance
status, radiotherapy dose and tumour size, thermal parameters involving both temperature
and duration of heating emerged as significant predictors of the various end-points. The
more commonly used CEM43T90 (cumulative equivalent minutes of T90 above 43 C) was
less influential than TRISE (based on the average T50 increase and the duration of heating,
normalised to the scheduled duration of treatment).
CEM43T90 and TRISE measured intraluminally correlate significantly and independently
with tumour control and survival. These findings stimulate further technological develop-
ment and improvement of deep hyperthermia, as they strongly suggest that it might be
worthwhile to increase the thermal dose for LACC, either by treatment optimisation or
by prolonging the treatment time. These results also confirm the beneficial effects from
hyperthermia as demonstrated in our earlier randomised trial, and justify applying radio-
therapy and hyperthermia as treatment of choice for patients with advanced cervical
cancer.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
At our department patients with locally advanced cervical
cancer (LACC) have been treated with combined radiotherapy
and hyperthermia (RT + HT) since 1990. From 1990 to 1996 aer Ltd. All rights reserved
fax: +31 10 7041022.
.nl (M. Franckena).randomised trial was conducted, in which radiotherapy alone
was compared to RT + HT for the treatment of locally ad-
vanced pelvic tumours.1 It showed a significant improvement
in local control and overall survival with the addition of
hyperthermia. The improvement was most apparent for.
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improvement is persistent after 12 years follow-up.3 After
the randomised trial was completed, RT + HT became a stan-
dard treatment approach for patients with LACC in the
Netherlands.4
From the clinical studies thus far performed, it is clear that
RT + HT improves treatment outcome compared to radiother-
apy alone. However, as the pelvic tumour control rate is still
only 53% at five years4, there is still a strong need to search
for ways to improve our treatment strategy. As has previously
been shown for radiotherapy dose escalation and the addition
of chemotherapy to RT + HT, we anticipate that optimising
the thermal dose delivered may further improve treatment
results in this patient group.5–8
For a variety of other tumour types that are treated with
radiotherapy and superficial hyperthermia, various thermal
dose parameters have been shown to relate to treatment out-
come significantly.9–17 For deep hyperthermia, much less is
known about the relationship between temperatures mea-
sured during treatment and treatment outcome.18–21
In this report we present the results of the retrospective
evaluation on which thermal dose parameters are of prognos-
tic value for treatment outcome when patients with LACC are
treated with RT + HT. We investigated the relation between
various thermal dose parameters and complete response rate,
pelvic tumour control, disease-specific survival and acute and
late toxicities.2. Patients and methods
From May 1990 to July 2005 458 patients with LACC were trea-
ted with RT + HT at the Erasmus Medical Center Rotterdam.
For 420 patients, temperature and power data are available.
For 38 patients, temperature and power data were
inaccessible.22
2.1. Patients
Patients were eligible for RT + HT if they required primary
standard radiotherapy for cervix cancer FIGO (International
Federation of Gynaecology and Obstetrics) stage IB2–IV. For
staging, we used the 4th edition of the UICC TNM Classifica-
tion of malignant tumours. In all patients, diagnosis was con-
firmed by histopathological examination. All patients
received a standard diagnostic work-up including a gynaeco-
logic examination under anaesthesia with a cystoscopy, a CT-
scan of the abdomen and a chest X-ray. An acceptable cardiac
condition defined as ASA (American Society of Anesthesiolo-
gists) classification of 2 or less was required and patients’ ex-
pected survival had to exceed 6 months. Patients with a
pacemaker or a metal implant in the pelvic region larger than
10 cm were excluded, since these are absolute contraindica-
tions for hyperthermia.
2.2. Radiotherapy
Radiotherapy was prescribed in accordance with the Dutch
Society for Radiotherapy and Oncology guidelines. External
beam radiotherapy was given in 23–28 daily fractions of 2.0–1.8 Gy, five times a week, to a total dose of 46.0–50.4 Gy using
a four-field box technique with 6–23 MV photons. The para-
aortic region was included in case of positive lymph nodes
along the common iliac artery or aorta. An additional pelvic
sidewall boost was given to patients with residual tumour
in the parametrium at the time of first brachytherapy.
Twenty-two patients received chemotherapy prior to radio-
therapy because of positive lymph nodes or bulky tumour
load.
Brachytherapy was scheduled for all patients and was
delivered using Iridium-192 (HDR) to a total dose of 17 Gy, ap-
plied in two fractions, or 18–21 Gy in three fractions or 30 Gy
in 60 h (LDR). Dose specifications and target volume definition
were according to the International Commission on Radiation
Units and Measurements (ICRU) report 50. Further details
have previously been published.42.3. Hyperthermia
Deep hyperthermia was prescribed once weekly to a total of
five times during the 5 weeks of external beam radiotherapy.
For all hyperthermia treatments the BSD-2000 system was
used (BSD Medical Corporation, Salt Lake City, Utah, USA),
with the Sigma-60 or Sigma-Eye applicator depending on
the patients’ size.23
For thermometry Bowman probes were placed in bladder,
rectum and vagina. Thermal mapping was performed every
5 min with a step size of 1 cm and a maximum map length
of 14 cm. The standard prescribed duration of a treatment
was 90 min, during which time temperatures were increased
to as high and homogeneous as patient tolerance and normal
tissue temperatures permitted: normal tissue temperatures
should not exceed 43 C during the first 60 min of a treatment,
and not exceed 44 C during the last 30 min. Besides the mea-
sured temperatures, information on too high temperatures
(hotspots) came from the patient. Patients were carefully in-
structed to mention any uncomfortable feelings that could
be suggestive of hotspots during treatment. If such com-
plaints occurred, treatment settings such as phase, ampli-
tude, frequency and power were adjusted to alleviate the
complaints.
2.4. Temperature and power measures
Based on the temperatures measured intraluminally, several
treatment parameters were calculated using RHyThM (Rotter-
dam Hyperthermia Thermal Modulator), which has been de-
scribed elsewhere in detail.24 The hyperthermia-related
parameters are described in Table 1. Cumulative Equivalent
Minutes of T90 at 43 C (CEM43T90) is a mathematical
description of the exponential relationship found in vivo and
in vitro, between temperature and exposure time; it is calcu-
lated as follows:22
CEM43T90 ¼
Xn¼5
n¼1
Z 90
0
DtRð43T90Þ
n is the number of treatments; Dt is the time interval of treat-
ment (min); T90 is the average all lumen T90 during Dt; R is a
constant; when T > 43 C R = 0.5, when T > 43 C R = 0.25.
Table 1 – Description of thermal parameters.
Abbreviation Parameter description
ALT20 Temperature exceeded by 20% of monitored sites in bladder, vaginal and rectal lumen together and averaged over all
treatments per patient (All Lumen T20)
ALT50 Temperature exceeded by 50% of monitored sites in bladder, vaginal and rectal lumen together and averaged over all
treatments per (All Lumen T50)
ALT90 Temperature exceeded by 90% of monitored sites in bladder, vaginal and rectal lumen together and averaged over all
treatments per patient (All Lumen T90)
VT50 Temperature exceeded by 50% of monitored sites in the whole vaginal lumen and averaged over all treatments per patient
(Vagina T50)
BT50 Temperature exceeded by 50% of monitored sites in the whole bladder lumen and averaged over all treatments per patient
(Bladder T50)
RT50 Temperature exceeded by 50% of monitored sites in the whole rectal lumen and averaged over all treatments per patient
(Rectum T50)
NIP Mean Net Integrated Power, averaged over all treatments*
CEM43T90 Cumulative equivalent minutes at a T90 of 43 C as described by Rau et al.21
TRISE Custom made thermal dose parameter based on ALT50 and duration of heating
NIPðmean Net Integrated PowerÞ :Pt¼maxt¼0 R ðPforward  PreflectedÞ  Dt
t = 0 is start of treatment, t = max is end of treatment, Pforward is the power forwarded during Dt, Preflected is the power reflected during Dt and Dt is
the time period of measurement.
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variable for each patient. The overall heating time cannot be
considered as such because the number of treatments and
the duration of a treatment are prescribed a priori, i.e. five
times and 90 min. Hence, we anticipated that a thermal dose
parameter expressing the temperature as dose but with the
actual treatment time normalised to the overall treatment
time of 450 minmay be aworthwhile parameter to investigate.
TRISE incorporates temperature and duration of heating,
but instead of transposing the measured temperatures to
equivalent minutes at a reference temperature, we simply
multiplied the T50 increase above 37 C during treatment with
the duration of treatment for all treatments, and normalised
it to 450 min; the scheduled total treatment time for all
patients.
TRISE ¼
Pn¼max
n¼1
ðALT50 37CÞ  dt
450
n is the number of treatments; dt is the duration of treatment;
ALT50 is the lumen T50, Table 1.2.5. Treatment outcome
Follow-up visits were planned in accordance with the Dutch
Association of Cancer Centers Guidelines. Information on
complete response, local control, survival and late toxicities
were gathered retrospectively.
Complete response rate was defined as the complete dis-
appearance of tumour within the irradiated volume and was
assessed by anamnestic information, gynaecological exami-
nation and supplemental investigations if indicated. Patients
who did not achieve a complete response were considered
pelvic failures at day 0.
Duration of pelvic tumour control was defined either as
the time elapsed since the date of the last radiotherapy frac-
tion and the date of local recurrence within the irradiated vol-
ume, or death of any cause.Disease-specific survival was defined as the time between
date of the last fraction of radiotherapy and death due to can-
cer-related cause, treatment-induced toxicityor last follow-up.
For acute hyperthermia-related toxicity analysis, the worst
grade toxicity a patient developed was included in this analy-
sis. The grading system used for acute hyperthermia-related
toxicity is described in Table 2. Acute hyperthermia-related
toxicity was defined as symptoms developing within 24 h
after a hyperthermia treatment.
Late radiation-induced toxicity was defined as toxicity due
to treatment that occurred at least 3 months after the last
fraction of radiotherapy and was classified according to the
CTC (Common Toxicity Criteria) scale, version 3. Patients
who developed a local recurrence were censored at the time
of recurrence.2.6. Statistical analysis
The primary end-points were complete response rate, pelvic
tumour control and disease-specific survival.
Secondary end-points were acute hyperthermia-related
and late radiation-induced toxicities.
For the thermal dose analyses, only patients were included
for whom temperature measurements were available for at
least 50% of the treatments they received, to ensure the tem-
perature measures depict a patients’ treatment accurately.
For patients with treatments without thermometry, the total
thermal dose was obtained through adding the average tem-
perature dose of all treatments with thermometry. This con-
cerned 221 treatments in 128 patients.
In the temperature analyses, all patientswere included, be-
cause variation between treatments is relatively small. In con-
trast to TRISE, CEM43T90 was not normally distributed, so its
natural logarithm (lnCEM43T90) was entered in the analyses.
The following baseline characteristics were entered in uni-
variate analysis (Table 3): FIGO stage of the tumour, World
Health Organisation performance status (WHO-PS), lymph
node status (N-status), histology, patient age, having received
Table 2 – Grading system used for classification of acute hyperthermia-related toxicity.
Grade Definition
1 Symptoms caused by hyperthermia treatment that lasted less than 3 days
2 Symptoms caused by hyperthermia treatment that lasted 3–14 days
3 Symptoms caused by hyperthermia treatment lasting 14 days or longer, or causing a delay or interruption of treatment
4 Symptoms caused by hyperthermia treatment that required surgery
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dose, we entered a bivariate parameter indicating whether
radiotherapy was given and completed as prescribed, i.e. 23–
28 daily fractions of 2.0–1.8 Gy external beam radiotherapy
combined with LDR, PDR or HDR brachytherapy at their
appropriate schedules, or not (RTc).
To ensure fair-sized subgroups, FIGO stage and WHO-PS
were regrouped for the multivariate analyses; FIGO stages IIA
and B were taken together (equivalent to T2 of the TNM classi-
fication) as were FIGO stages IIIA and IIIB (T3 of the TNM clas-
sification). WHO-PS was regrouped as WHO 0 or larger than 0.
For the toxicity analyses, the subcutaneous fat thickness,
patients’ anterior-posterior and lateral diameter were also en-
tered. These measures were determined on the CT-scan madeTable 3 – Patient, tumour and treatment characteristics.
FIGO stage IB2 14 (3%)
IIA 27 (6%)
IIB 146 (35%)
IIIA 21 (5%)
IIIB 158 (38%)
IVA 54 (13%)
N-status Nx 47 (11%)
N0 239 (57%)
N1 134 (32%)
Histology SCC 358 (85%)
AC 38 (9%)
Other 20 (5%)
Unknown 4 (1%)
WHO-PS 0 262 (62%)
1 123 (29%)
2 33 (8%)
3 2 (1%)
Chemotherapy Yes 22 (5%)
No 398 (95%)
RTc Yes 360 (86%)
No 60 (14%)
Number of HT 1 15 (3%)
2 16 (4%)
3 17 (4%)
4 73 (16%)
5 299 (73%)
Age Mean 57 years (22–89)
Overall treatment time Mean 40.5 days (7–115)
Tumour size Mean 8.9 cm (3.9–16.5 cm)
FIGO, International Federation of Gynaecology and Obstetrics; N-
status, lymph node status; SCC, squamous cell carcinoma; AC,
adenocarcinoma; WHO-PS, World Health Organisation Perfor-
mance Status; RTc, radiotherapy completed as planned (yes) or not
(no); HT, hyperthermia treatments.for treatment planning. For each significant thermal parame-
ter, multivariate models were constructed incorporating all
significant baseline characteristics on any end-point.
For analyses on response rate and acute hyperthermia-
related toxicity, logistic regression was used. Cox regression
was used for analyses on pelvic tumour control, disease-
specific survival and late toxicity. P-values below 0.05 were
considered significant.
For depicting the relationship between thermal dose and
treatment outcome (Fig. 1), we grouped the thermal dose
parameters at their 20th percentiles.
3. Results
Baseline characteristics of the 420 patients with LACC are
summarised in Table 3.
3.1. Thermal parameters
Hyperthermia treatment parameters are summarised in Table
4. Overall, the temperatures measured are comparable to
what we and others found previously with an ALT50 of
40.6 C.19,22 The CEM43T90 was relatively low and showed
wide variation, with a mean of 5.05. Our new parameter TRISE
was 2.96 on average. Correlation between various thermal
parameters is shown in Table 5.
Complete response rate (CR-rate): Three hundred and
twenty-nine patients (78%) achieved a complete response fol-
lowing RT + HT, 65 (16%) patients had a partial response, 13
(3%) stable disease and 5 (1%) patients had progressive dis-
ease during treatment. For 8 patients, no information on tu-
mour response could be gathered (2%). FIGO stage, tumour
size, N-status, WHO-PS and RTc emerged as significant base-
line characteristics from the univariate analysis (Table 6a).
The mean intraluminal temperature measured (ALT50) for
complete responders (CRs) was similar to that of the non-
complete responders (NCRs) (40.5 C and 40.6 C, respec-
tively). There was a slight difference in CEM43T90 between
the CRs and the NCRs; 5.23 versus 4.35. Of the thermal param-
eters, TRISE and lnCEM43T90 were significant. In multivariate
analysis, the influence of lnCEM43T90 lost its significance
(p = 0.195), but TRISE remained significant (p = 0.013). The
CR-rate per thermal parameter group is depicted in Fig. 1a.
3.2. Pelvic tumour control (PTC)
PTC was 65% (95% confidence interval (CI) 60–70%) one year
after treatment, and 53% (95% CI 47–58%) at five years. From
univariate analysis, FIGO stage, tumour size, N-status, age,
WHO-PS and RTc emerged as significant baseline characteris-
tics (Table 6a).
Table 5 – Pearson’s correlation coefficients of thermal
parameters.
CEM43T90 TRISE NIP
ALT20 0.36 0.31 0.07
ALT50 0.76 0.54 )0.04
ALT90 0.77 0.53 )0.02
VT50 0.72 0.43 )0.09
RT50 0.65 0.43 0.11
BT50 0.65 0.54 0.04
NIP )0.05 0.19 xx
TRISE 0.65 xx 0.19
Table 4 – Hyperthermia treatment parameters.
Parameter Average Standard deviation
ALT20 41.1 C 0.31
ALT50 40.6 C 0.55
ALT90 39.8 C 0.55
VT50 40.3 C 0.74
BT50 40.8 C 0.61
RT50 40.6 C 0.51
NIP 630 kJ 126
CEM43T90 5.05 min 4.18
TRISE 2.96 C 2.96
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patients who developed a pelvic failure was similar to that of
patients who did not (40.5 C and 40.6 C, respectively). There
was a slight difference in CEM43T90 between the two groups;
4.40 versus 5.50. After adjustment for other significant fac-
tors, lnCEM43T90 and TRISE remained of significant influence
(p = 0.019 and 0.021, Table 6b). The 3-year PTC rate per ther-
mal parameter group is depicted in Fig. 1b.Table 6a – Univariate analysis for patient and tumour
characteristics and thermal parameters on complete
response rate (CR-rate), pelvic tumour control (PTC) and
disease-specific survival (DSS) (p-values).
CR-rate PTC DSS
FIGO stage 0.000 0.000 0.000
N-status 0.027 0.034 0.047
Tumour size 0.000 0.022 0.002
Histology 0.050 0.374 0.209
WHO-PS 0.000 0.000 0.001
Age 0.319 0.037 0.166
Chemotherapy (yes or no) 0.092 0.103 0.240
RTc 0.000 0.000 0.000
OTT (days) 0.246 0.185 0.671
ln CEM43T90 0.025 0.002 0.002
TRISE 0.000 0.000 0.000
NIP 0.070 0.015 0.007
ALT20 0.683 0.051 0.036
ALT50 0.878 0.108 0.038
ALT90 0.990 0.091 0.048
VT50 0.259 0.424 0.125
BT50 0.795 0.043 0.062
RT50 0.479 0.098 0.0273.3. Disease-specific survival (DSS)
DSS was 75% one year after treatment (95% CI: 71–79%) and
47% at 5 years (95% CI: 41–53%). Significant baseline charac-
teristics in univariate analysis were again FIGO stage, tumour
size, N-status, WHO-PS and RTc (Table 6a). CEM43T90 for pa-
tients who ultimately died of cervical cancer was 4.45 on aver-
age and 5.47 for patients who did not die of cervical cancer.
The ALT50 was again comparable in both groups, 40.5 C ver-
sus 40.6 C. After adjustment for significant baseline charac-
teristics in multivariate analysis, lnCEM43T90 and TRISE
remained of significant influence on DSS (p = 0.001 and
0.002, Table 6b). The 3-year DSS rate per thermal parameter
group is depicted in Fig. 1c.3.4. Acute hyperthermia-related toxicity
One hundred and fifty-three patients developed acute hyper-
thermia-related toxicity to the subcutaneous tissues. Fifty-
one percent of patients (80/153) were grade 1, 39% grade 2
(60/153), 9% were grade 3 (16/153) and only one patient re-
quired a surgical intervention due to her subcutaneous burn
(0.6% grade 4). In univariate analysis, the mean power applied
(NIP) was significant as well as TRISE (Table 7). Patients who
developed acute hyperthermia-related toxicity received 46 kJ
more than those who did not and their TRISE was 1.7 C high-
er. Because of the expected mechanism behind the develop-
ment of subcutaneous burns, extra anatomy-related factors
were entered in univariate analysis, such as the thickness of
the subcutaneous fat and the patients’ size. In patients who
developed toxicity the dorsal subcutaneous fat was thicker
(0.7 cm) and they were larger in anterior-posterior (0.9 cm)
and lateral (1.5 cm) directions. After adjustment for these fac-
tors, NIP lost its significant influence, but TRISE did not
(p = 0.010).
Fourteen patients developed complaints related to the
peripheral nervous system during and/or after a hyperther-
mia treatment. For 12 patients, complaints were restricted
to CTC grade 2, and five developed grade 3 neurotoxicity. A de-
tailed description and evaluation of significant factors influ-
encing neurotoxicity after deep hyperthermia was
previously published.253.5. Late radiation-related toxicity
CTC grade 3 or higher was diagnosed in 6% of patients in the
first year after treatment, and in 12% of patients at 5 years
after treatment (95% CI: 7–17%). Of all factors studied, only pa-
tient size was of significant influence on long-term radiother-
apy-induced toxicity, both in the AP direction and in the
lateral direction (p = 0.01 and p = 0.02).4. Discussion
To our knowledge, this study is the largest study investigating
the relation between various simple and complex thermal
dose parameters and complete response rate, pelvic tumour
control, disease-specific survival and acute and late toxicities
in patients with LACC treated with RT + HT.
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Fig. 1a – Complete response rate (CR-rate) per thermal dose parameter group.
Table 6b – Multivariate analysis after adjustment for
other significant factors (p-values).
CR-rate PTC DSS
ln CEM43T90 0.195 0.019 0.001
TRISE 0.027 0.021 0.002
NIP 0.757 0.129 0.060
ALT20 0.891 0.320 0.212
ALT50 0.331 0.702 0.318
ALT90 0.323 0.685 0.370
VT50 0.194 0.942 0.354
RT50 0.810 0.510 0.166
BT50 0.347 0.565 0.645
FIGO, International Federation of Gynaecology and Obstetrics; N-
status, lymph node status; WHO-PS, World Health Organisation
Performance Status; RTc, radiotherapy completed as planned or
not; ln CEM43T90, natural logarithm of CEM43T90.
0
0.2
0.4
0.6
0.8
1
C1 C2 C3 C4 C5
CEM43T90 grouped
3 
ye
ar
 P
TC
 ra
te
0
0.2
0.4
0.6
0.8
1
T1 T2 T3 T4 T5
TRISE grouped
3 
ye
ar
 P
TC
 ra
te
Fig. 1b – 3-Year pelvic tumour control (PTC) rate per thermal
dose parameter group.
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parameters that include both height of temperature and
duration of heating (CEM43T90 and TRISE) and all disease
control end-points. After adjustment for other correlating fac-
tors in multivariate analysis, TRISE remains significantly cor-
related with response and survival and CEM43T90 with
survival.
Overall, treatment outcome is relatively meager than other
published series, both since and before 1996. It was a major
point of criticism of the Dutch Deep Hyperthermia Trial
(DDHT) and can be explained by the bad prognostic character-
istics of the patients that were included in the trial.2 The
Table 7 – Univariate analysis for acute hyperthermia-
related skin/subcutaneous toxicity.
p-Value
FIGO stage 0.362
N-status 0.118
Tumour size 0.942
Histology 0.484
WHO-PS 0.046
Age 0.953
Chemotherapy (yes or no) 0.363
OTT (days) 0.219
RTc (yes or no) 0.025
Thickness subcutaneous fat dorsal 0.004
Ventral 0.072
Lateral 0.360
Patient size anterior to posterior 0.008
Patient size lateral to lateral 0.001
ln CEM43T90 0.234
TRISE 0.002
NIP 0.000
ALT20 0.911
ALT50 0.377
ALT90 0.728
VT50 0.061
RT50
BT50 0.061
FIGO, International Federation of Gynaecology and Obstetrics; N-
status, lymph node status; WHO-PS, World Health Organisation
Performance Status; OTT, overall treatment time; RTc, radiother-
apy completed as planned or not.
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Fig. 1c – 3-Year disease-specific survival (DSS) rate per
thermal dose parameter group.
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more: since we have shown the large benefit of the addition
of hyperthermia to radiotherapy, we tend to accept patients
who are older, have larger tumours and are in worse general
condition compared to the period of the DDHT.4 Large tu-
mour, older age and worse general condition have a negative
influence on treatment outcome for patients with cervical
carcinoma, as was previously shown by others.7,26–30
For the patient group presented here, there is no real con-
trol group to which we can compare the results. What we
have done is an evaluation of the results compared to those
in the RT + HT arm in the DDHT. We found that, after adjust-Table 8 – Randomised studies comparing RT to RT + HT for loc
FIGO n CR-rate
RT RT + H
Datta31 IIIB 64 58 74
Sharma32 II, III 50
Hong Wei33 IIB, IIIB 120 48 72*
Harima34 IIIB 40 50 80*
Vasanthan35 IIB–IV 110
DDHT2,3 IIB–IV 114 57 83*
* Significant difference.
a At 2 years.
b At 1.5 years.
c At 3 years.
d At 12 years.ment for differences in prognostic factors, the results are sim-
ilar and indirectly confirm the beneficial effects from
hyperthermia that we have shown in our earlier randomised
trial.4
Other researchers have previously shown a similar benefi-
cial effect of adding hyperthermia to standard radiotherapy
for LACC (Table 8). Only one35 of six randomised trials showed
no beneficial effect of adding hyperthermia and this trial was
heavily criticised because of flaws in its design and inade-
quate heating techniques.35–37
The combination of chemotherapy and radiation is cur-
rently the standard of treatment in most countries, but re-
cently a meta-analysis based on individual patient dataally advanced cervical cancer.
Pelvic control Overall survival
T RT RT + HT RT RT + HT
46 67a 73 81a
50 70b
49 80c,* 48 58c
80 70c 73 73c
37 56d,* 20 37d,*
1976 E U R O P E A N J O U R N A L O F C A N C E R 4 5 ( 2 0 0 9 ) 1 9 6 9 –1 9 7 8further strengthens earlier suggestions that the addition of
chemotherapy to radiotherapy is less beneficial in the higher
stages, while hyperthermia has shown its additional value
especially in the higher stages.38,39
Many of the parameters that we found to be of prognostic
importance in our patient group are known prognostic factors
for patients with cervical carcinoma. FIGO stage, tumour size
measured on CT-scan, lymph node status, general condition,
patient age and radiation dose are known prognostic factors
for patients with cervical carcinoma. The prognostic impor-
tance of hyperthermia dose, even after adjustment for all
other prognostic factors, is a new finding in this study. Previ-
ous research in this area was limited to populations too small
to allow for a multivariate analysis.18–21
The finding of a thermal dose effect relationship for dose
parameters derived from intraluminal measurements is fur-
ther important for deep hyperthermia treatment guidelines.
Apparently, interstitial measurements are not required to
monitor the quality of treatment for cervical cancer.
Our finding of a thermal dose effect relationship suggests
that the clinical outcome of RT + HT for LACC can be improved
by an increase in thermal dose (Fig. 2). The dose-effect curve in
Fig. 2 was constructed using the coefficients, b0 and b1, found
in univariate analysis. From this figure, we can hypothesise
that adding one treatment to the current schedule, results in
a 4% increase in the probability of a complete response for pa-
tients who receive the average TRISE dose or less.
Naturally, a higher dose can be achieved in twoways; high-
er temperatures, or longer duration of heating. We do not ex-
pect to achieve higher temperatures with our currently used
strategy as it already aims at heating to maximum patient tol-
erance. To further increase temperature, hyperthermia treat-
ment planning may be a useful tool.40 Wust et al. conducted a
simulation study and concluded that an increase in T90 of
1.9 C can be achieved with temperature optimisation using
hyperthermia treatment planning. However, data on the clin-Fig. 2 – Complete response probability or p(CR) as a function
of TRISE.ical effectiveness of hyperthermia treatment planning are
limited to date. In view of our current and previous results,
longer duration of heating seems a worthwhile option to ex-
plore, especially for patients in the lower thermal dose
groups.
In conclusion, the results of this large group of patients
treated with RT + HT, confirm the results of RT + HT that we
have seen in the DDHT and form an external validation of
that trial. Currently, combined radiotherapy and cisplatin is
considered a standard treatment for patients with cervical
carcinoma worldwide. However, we also find it justified to
combine radiotherapy with hyperthermia instead of cisplatin,
since the beneficial effects of both modalities are of the same
magnitude.41 In any case, we strongly recommend RT + HT for
patients with a contraindication for cisplatin, due to e.g. poor
general condition, insufficient renal function or extended
field radiotherapy and many Dutch radiotherapy institutes
have adopted this view since 1996.
The situation in the Netherlands, where in fact two stan-
dard treatment approaches coexist for locally advanced cervi-
cal cancer, gives us the unique opportunity to compare the
two approaches. In an ongoing Dutch multicenter phase III
trial, the two combined treatments are compared questioning
which patients benefit most fromwhich additional treatment.
Another interesting question is of coursewhether the effect of
radiotherapy plus cisplatin can be further improved by the
addition of hyperthermia to the treatment schedule. This
question is addressed in an international multicenter phase
III trial.Conflict of interest statement
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